Lilly’s Alimta dosage patent invalidated at English High Court

16-05-2014

Lilly’s Alimta dosage patent invalidated at English High Court

Photo: Eli Lilly and Company

The English High Court has ruled that a patent covering vitamin dosage regimens for Eli Lilly’s lung cancer drug Alimta (pemetrexed disodium) would not be infringed by generic competitors.


Eli Lilly, Alimta, Actavis, English High Court, dosage regimen patent

LSIPR